All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Domain Therapeutics SA has received clinical trial application (CTA) clearances in France and Belgium for its immuno-oncology program DT-9081, allowing the initiation of a phase I trial for solid tumors.
